This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A glycinamide compound ~~Glycinamide derivatives~~ of formula I

A-D-B (I)

wherein

D is a bivalent glycine amide moiety, or a derivative thereof ~~therof~~,

A is an [[a]] unsubstituted or substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L')$_\alpha$; [[,]] ~~where~~

L is a 5, 6 or 7 membered cyclic structure containing 0-4 members selected from nitrogen, oxygen and sulfur ~~, preferably selected from the group consisting of aryl, heteroaryl, arylene and heteroarylene,~~ bound directly to D; [[,]]

L' comprises an optionally substituted cyclic moiety having at least 5 members and containing 0-4 members selected from nitrogen, oxygen and sulfur, wherein L' is optionally substituted by at least one substituent selected from -$SO_\beta R_x$, -$C(O)R_x$ and -$C(NR_y)R_z$; ~~, preferably selected from the group consisting of aryl, heteroaryl, aralkyl, cycloalkyl and heterocyclyl,~~

M is a bond or a bridging group having at least one atom; [[,]]

α is an integer of from 1-4; ~~and~~

~~each cyclic structure of L and L' contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L' is preferably substituted by at least one~~

~~substituent selected from the group consisting of~~

~~SO_pR_s, $C(O)R_s$ and $C(NR_y)R_z$;~~

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms, ~~preferably of up to 20 carbon atoms,~~ comprising at least one 5-, 6-, or 7-membered cyclic structure, ~~preferably a 5- or 6-membered cyclic structure,~~ bound directly to D and containing 0-4 members selected from ~~of the group consisting of~~ nitrogen, oxygen and sulfur; ~~, wherein said cyclic structure directly bound to D is preferably selected from the group consisting of aryl, heteroaryl and heterocyclyl,~~

where when B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from halogen, up to per-halo, and W_γ;

R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo; ~~,~~

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b; ~~, where~~

R_a and R_b are

a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based

substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

~~where B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W$_\gamma$ where~~

γ is 0-3;

W is, in each case, ~~wherein each W is~~ independently selected from ~~the~~

~~group consisting of~~ -CN, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the groups consisting of -CN, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$ and halogen up to per-halo; ~~with each~~

R^5 is, in each case, independently ~~selected from~~ H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen; [[,]] ~~wherein~~

Q is -O-, -S-, $-N(R^5)-$, $-(CH_2)_\beta-$, -C(O)-, -CH(OH)-, $-(CH_2)_\beta O-$, $-(CH_2)_\beta S-$, $-(CH_2)_\beta N(R^5)-$, $-O(CH_2)_\beta-$, $-CHHal-$, $-CHal_2-$, -S-(CH_2)-, or ~~-S-(CH_2)-~~ ~~and~~ $-N(R^5)(CH_2)_\beta-$; ~~where β = 1-3, and~~

β is 1-3;

Hal is halogen; ~~and~~

Ar is 5- or 6-member aromatic structure containing 0-2 members selected from ~~the group consisting of~~ nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by $Z_{\delta 1}$; ~~wherein~~

$\delta 1$ is 0 to 3; and ~~each~~

Z is, in each case, independently selected from ~~the group consisting~~ -CN, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, -

NR^5R^5, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from ~~the group consisting of~~ CN, $-CO_2R^5$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-SO_2R^5$, $-SO_3H$, $-NR^5R^5$, $-NR^5C(O)OR^5$, and $-NR^5C(O)R^5$; [[,]] ~~and the the~~ or

a physiologically acceptable derivative, salts or solvate ~~derivatives, salts and solvates~~ thereof.

2. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1, ~~characterised in that~~ wherein

each M_x independently from one another, represents a bond or is a bridging group [[,]] selected from ~~the group consisting of~~ $(CR^5R^5)_h$, and ~~or~~ $(CHR^5)_h$-Q-$(CHR^5)_i$, ~~wherein~~

Q is ~~selected from a group consisting of~~ O, S, N-R^5, $(CHal_2)_j$, $(O\text{-}CHR^5)_j$, $(CHR^5\text{-}O)_j$, $CR^5{=}CR^5$, $(O\text{-}CHR^5CHR^5)_j$, $(CHR^5CHR^5\text{-}O)_j$, C=O, C=S, C=NR^5, $CH(OR^5)$, $C(OR^5)(OR^5)$, C(=O)O, OC(=O), OC(=O)O, $(C{=}O)N(R^5)C(=O)$, $OC(=O)N(R^5)$, $N(R^5)C(=O)O$, CH=N-NR^5, S=O, SO_2, SO_2NR^5, ~~or~~ ~~und~~ NR^5SO_2, ~~wherein~~

~~R^5 is in each case independently selected from the meanings given above, preferably hydrogen, halogen, alkyl, aryl, aralkyl,~~

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, ~~preferably 0, 1, 2 or 3,~~ and

j is 1, 2, 3, 4, 5 or 6~~, preferably 0, 1, 2 or 3~~.

3. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1, selected from the compounds of formula II,



II

wherein

Ar^1, Ar^2 are each, ~~selected~~ independently from one another, selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and ~~und~~ S,

R^8, R^9 and R^{10} are independently selected from ~~a group consisting of~~ H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_nR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, CH=$CHCOOR^{11}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, ~~wherein~~

R^{11}, R^{12} are independently selected from ~~a group consisting of~~ H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or,

in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle ~~heterocyclus~~ which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

R^{13}, R^{14} are independently selected from ~~a group consisting of~~ H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from ~~the group consisting of~~ alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 ~~and preferably 5 to 10 carbon atoms~~ which are optionally substituted by one or more substituents, selected from ~~a group consisting of~~ A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from ~~a group consisting of~~ A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from ~~a group consisting of~~ H, A, and $(CH_2)_mAr^5$, ~~wherein~~

Ar^5 ~~Ar~~^{6} is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from ~~a group consisting of~~ methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-Q-$(CHR^{12})_i$, ~~wherein~~

Q is selected from ~~a group consisting of~~ O, S, N-R^{15}, $(CHal_2)_j$, $(O\text{-}CHR^{18})_j$, $(CHR^{18}\text{-}O)_j$, $CR^{18}{=}CR^{19}$, $(O\text{-}CHR^{18}CHR^{19})_j$, $CHR^{18}CHR^{19}\text{-}O)_j$, C=O, C=S, C=NR^{15}, CH(OR^{15}), C(OR^{17})(OR^{20}), C(=O)O, OC(=O), OC(=O)O, C(=)N(R^{15}), N(R^{15})C(=O), OC(=O)N(R^{15}), N(R^{15})C(=O)O, CH=N-O, CH=N-NR^{15}, OC(O)NR^{15}, $NR^{15}C(O)O$, S=O, SO_2, SO_2NR^{15} and ~~and~~ $NR^{15}SO_2$, ~~wherein~~

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, ~~and~~

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$, ~~wherein~~

R^{21} is H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$, ~~independently selected from the meanings given for R^{13}, R^{14}, and~~

R^{22} is H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, ~~independently selected from the meanings given for R^{11}, R^{12},~~

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, ~~preferably 0, 1 or 2,~~

u is 0, 1, 2 or 3, ~~preferably 0, 1 or 2,~~

and

Hal is independently selected from ~~a group consisting of~~ F, Cl, Br and I;

and the salts and solvates thereof.

4. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1, selected from the compounds of formula IIa, IIb, IIc, IId, IIe, IIf, IIg and IIh,



IIa



IIb



IIc



IId



IIe



IIf



IIg



IIh

wherein

R^8, R^9 and R^{10} are independently selected from ~~a group consisting of~~ H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_mSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, CH=$CHCOOR^{11}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, ~~wherein~~

R^{10} can also be H,

R^{11}, R^{12} are independently selected from ~~a group consisting of~~ H, A, $(CH_2)_mAr^3$ and $(CH_2)_m$Het, or, in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they

are bound to, a 5-, 6- or 7-membered heterocycle ~~heterocyclus~~ which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

R^{13}, R^{14} are independently selected from ~~a group consisting of~~ H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from ~~the group consisting of~~ alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 ~~and preferably 5 to 10~~ carbon atoms which are optionally substituted by one or more substituents, selected from ~~a group consisting of~~ A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from ~~a group consisting of~~ A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from a group consisting of H, A, and $(CH_2)_mAr^5$, ~~wherein~~

Ar^5 ~~Ar^6~~ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from ~~a group consisting of~~ methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5; ~~or~~ ~~R^{10} is H~~

p is ~~p, r are independently from one another~~ 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, ~~preferably 0, 1 or 2,~~

u is 0, 1, 2 or 3,

Y is selected from O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$, ~~wherein~~

R^{21} is H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$, ~~independently selected from the meanings given for R^{13}, R^{14}, and~~

R^{22} is H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, ~~independently selected from the meanings given for R^{11}, R^{12},~~

and the salts and solvates thereof.

5. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1, selected from















and



6. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1 as a medicament.

7. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 1 as a kinase inhibitor.

8. (Currently Amended): A glycinamide compound ~~Glycinamide derivative~~ according to claim 7, wherein said ~~characterized in that the~~ kinases are selected from raf-kinases.

9. (Cancelled):

10. (Currently Amended): A pharmaceutical ~~Pharmaceutical~~ composition comprising one or more compounds according to claim 1, and ~~9, characterised in that it contains~~ one or more additional compounds, selected from ~~the group consisting of~~ physiologically acceptable excipients, auxiliaries, adjuvants, carriers and other pharmaceutical active ingredients.

11. (Currently Amended): A process ~~Process~~ for the manufacture of a pharmaceutical composition comprising processing ~~, characterised in that~~ one or more

compounds according to claim 1 and one or more compounds [[,]] selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to claim 1, ~~is processed~~ by mechanical means into a pharmaceutical composition that is suitable as dosage form ~~dosageform~~ for application and/or administration to a patient.

12. (Cancelled):

13. (Currently Amended): A method for ~~Use of a compound according to claim 1 one of the claims 1 to 5 in~~ the treatment and/or prophylaxis of disorders in a patient caused, mediated and/or propagated by kinases, said method comprising administering to said patient one or more compounds according to claim 1.

14. (Currently Amended): A method for ~~Use of a compound according to claim 1 for producing a pharmaceutical composition for the~~ treatment and/or prophylaxis of disorders in a patient caused, mediated and/or propagated by kinases, said method comprising administering to said patient a composition according to claim 10.

15. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorders are caused, mediated and/or propagated by raf-kinases.

16. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorders are selected from ~~the group consisting of~~ hyperproliferative and nonhyperproliferative disorders.

17. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorder is cancer.

18. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorder is noncancerous.

19. (Currently Amended): A method ~~Use~~ according to claim ~~13~~, 18, wherein said ~~characterised in that the~~ noncancerous disorder is ~~disorders are~~ selected from ~~the group consisting of~~ infection, psoriasis, arthritis, inflammation, endometriosis, scarring, benign ~~begnin~~ prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

20. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorders are selected from ~~the group consisting of~~ brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukemia ~~leukaemia~~ and acute leukemia ~~leukaemia~~.

21. (Currently Amended): A method ~~Use~~ according to claim 13, wherein said ~~characterised in that the~~ disorders are selected from ~~the group consisting of~~ arthritis, restenosis, [[;]] fibrotic disorders, [[;]] mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative diseases.

22. (Cancelled):

23. (Currently Amended): A method ~~Use~~ according to claim 15, wherein said ~~22,~~ ~~characterised in that the~~ raf-kinase is selected from ~~the group consisting of~~ A-Raf, B-Raf and c-Raf-1.

24. (Currently Amended): A method ~~Method~~ for the treatment and/or prophylaxis of disorders, comprising administering ~~characterised in that~~ one or more compounds according to claim 1 ~~is administered~~ to a patient in need of such a treatment.

25. (Currently Amended): A method ~~Method~~ according to claim 24, wherein said ~~characterised in that the~~ one or more ~~of said~~ compounds are administered as a pharmaceutical composition.

26. (Cancelled):

27. (Currently Amended): A method ~~Method for the treatment~~ according to claim ~~26, characterised in that the disorder,~~ 13, wherein said disorder is cancerous cell growth mediated by raf-kinase.

28. (Currently Amended): A method ~~Method~~ for producing a compound ~~compounds~~ of formula II, said method comprising: ~~characterised in that~~

~~a)~~

reacting a compound of formula III



III

wherein

L^1 is Cl, Br, I, OH, a reactive esterified OH-group or a diazonium moiety, ~~and R^8, p, Ar^1, Y are as defined in claim 3,~~

R^8 is selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_qR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$,

$(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,
$(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$,
$C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$,
$(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, CH=CHCOOR^{11},
CH=CHCH$_2$NR^{11}R^{12}, CH=CHCH$_2$NR^{11}R^{12}, CH=CHCH$_2$OR^{13},
$(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$,
$(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$,
$(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
$(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$,
$(CH_2)_nOCN$ and $(CH_2)_nNCO$,

p is 0, 1, 2, 3, 4 or 5,

Ar^1 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S,

Y is selected from O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

R^{11}, R^{12} are independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_m$Het, or, in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5,

R^{13}, R^{14} are independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_m$Het,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from H, A, and $(CH_2)_mAr^5$,

Ar^5 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

u is 0, 1, 2 or 3,

R^{21} is H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_m$Het,

R^{22} is H, A, $(CH_2)_mAr^3$ and $(CH_2)_m$Het,

~~b)~~

with a compound of formula IV,



IV

wherein

L^2, L^3 are independently from one another H or a metal ion, ~~and R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3,~~

R^9 and R^{10} are independent from one another selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_nR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, CH=CHCOOR^{11}, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

q is 0, 1, 2, 3, or 4,

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-O-$(CHR^{12})_i$,

Ar^2 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S,

r is 0, 1, 2, 3, 4 or 5, and

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6;

r is 0, 1, 2, 3, 4 or 5

and optionally isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

29. (Currently Amended): A compound ~~Compound~~ of formula III,



III

wherein

L^1 is Cl, Br, I, OH, a reactive esterified OH-group or a diazonium moiety, ~~and R^8, p, Ar^1, Y are as defined in claim 3~~

R^8 is selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_nR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11},

$(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{11}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

p is 0, 1, 2, 3, 4 or 5,

Ar^1 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S,

Y is selected from O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$,

R^{11}, R^{12} are independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_m$Het, or, in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

n, m are independently of one another 0, 1, 2, 3, 4, or 5,

A is selected from alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

R^{13}, R^{14} are independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_n$Het,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, NR^{15} $CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from H, A, and $(CH_2)_mAr^5$,

Ar^5 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

u is 0, 1, 2 or 3,

R^{21} is H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

R^{22} is H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$.

30. (Currently Amended): A compound ~~Compound~~ of formula IV,



IV

wherein

L^2, L^3 are independently from one another H or a metal ion, ~~and R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3~~

R^9 and R^{10} are independent from one another selected from H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_kR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$, $C(R^{13})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{11}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{11}$, $(CH_2)_nCHR^{13}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,

A is selected from alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

R^{11}, R^{12} are independently selected from H, A, $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or, in $NR^{11}R^{12}$, R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional hetero atoms, selected from N, O an S,

k, n, m are independently of one another 0, 1, 2, 3, 4, or 5,

R^{13}, R^{14} are independently selected from H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_nHet$,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, NR^{15} $CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

q is 0, 1, 2, 3, or 4,

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-Q-$(CHR^{12})_i$,

Ar^2 is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from H, A, and $(CH_2)_mAr^5$,

Ar^5 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

u is 0, 1, 2 or 3,

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

r is 0, 1, 2, 3, 4 or 5.

31. (New): A compound according to claim 3, wherein

Ar^1 is phenyl, pyridinyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl, preferably phenyl, pyridinyl or isoxazolyl and especially phenyl or oxazolyl,

p is 1, 2 or 3,

R^8 is selected from the group consisting of alkyl comprising 1 to 4 carbon atoms, alkoxy comprising 1 to 4 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, perhaloalkyl comprising 1 to 4 carbon atoms, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCOOR^{11}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nSO_2NR^{11}R^{12}$ and $(CH_2)_nS(O)_uR^{13}$, wherein

n is 0 or 1,

u is 0 or 2,

q is 0 or 1, and

X is O, S, NR^{15}, $CHOR^{11}$, CH_2, CH_2CH_2, OCH_2, CH_2O, OCH_2CH_2, or CH_2CH_2O.

32. (New): A compound according to claim 31, wherein A^2 is phenyl or pyridinyl.

33. (New): A compound according to claim 31, wherein X is O or S.

34. (New): A compound according to claim 31, wherein Y is O or S.

35. (New): A compound according to claim 31, wherein A^1 is phenyl or oxazolyl.

36. (New): A compound according to claim 31, wherein A^2 is pyridinyl.

37. (New): A compound according to claim 31, wherein X is O.

38. (New): A compound according to claim 31, wherein Y is O.